Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00820560 · ClinicalTrials.gov registry record · Phase 1
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00820560 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 41 participants.
The verdict
NCT00820560, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
To establish the maximum tolerated dose (MTD) of INCB007839 given as multiple doses for 28 days and to determine if a higher MTD can be established when INCB007839 is administered in combination with prophylactic anticoagulation and with a 2 and a half day (5 doses) treatment interruption every two weeks.
Interventions
- DRUG INCB007839
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2005-01 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00820560
The ClinicalTrials.gov registry entry for NCT00820560 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB007839 is the first listed.
NCT00820560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00820560 about?
NCT00820560 is a clinical study titled "Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors". To establish the maximum tolerated dose (MTD) of INCB007839 given as multiple doses for 28 days and to determine if a higher MTD can be established when INCB007839 is administered in combination with prophylactic anticoagulation and with a 2 and a half day (5 doses) treatment interruption every two ...
What is the current status of trial NCT00820560?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2005-01. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00820560?
The interventions under investigation include: INCB007839 (DRUG).
Who is sponsoring clinical trial NCT00820560?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.